Nanobiotix Shares Hit a Record High of €38.40, Up 7.61%
The French biotech company experienced another euphoric session this Thursday, May 7. The stock reached an all-time high of €38.40 intraday, before settling at €37.34, marking a 7.61% increase. Nanobiotix leads the SBF 120 while the index remains nearly stable.
Top Performer in the SBF 120 and New Record High
The stock price of Nanobiotix reached a record high of €38.40 during the session, surpassing the previous peak of €38.36. At €37.34 midday, the stock recorded the highest rise in the SBF 120, ahead of Soitec (+5.62%) and Atos (+5.5%). The increase amounts to 32.22% over seven days and 1,138% over a year.
The surge follows the rally that began with the FDA’s approval of an amendment to the Phase 3 trial protocol of NANORAY-312, announced on Monday. This amendment, submitted by Johnson & Johnson as the global sponsor, modifies the analysis framework of the head and neck cancer study and could accelerate the development timeline of the candidate JNJ-1900 (NBTXR3), as mentioned in the press release published on Monday. The stock had already jumped by 12% the previous session.
RSI at 70 and Price Breaks Above Bollinger Bands
The technical setup reflects the market excitement. The price at €37.34 is significantly above the upper Bollinger Band set at €31.79, indicating a strong overbought signal. The RSI has reached 70, entering the overbought zone, following a more than 32% rise over the week.
The gap with moving averages has widened: the MM50 is at €27.36 and the MM200 at €18.20, which are approximately 36% and 105% below the current price, respectively. The resistance at €34.70 was breached during the session. The financial calendar does not list any upcoming events; focus remains on the NANORAY-312 trial schedule led by Johnson & Johnson.
